About Boundless Bio
Boundless Bio is a company based in San Diego (United States) founded in 2018. Boundless Bio has raised $251.99 million across 4 funding rounds from investors including Fidelity Investments, Bayer and ARE. The company has 64 employees as of December 31, 2024. Boundless Bio offers products and services including ecDTx Therapies. Boundless Bio operates in a competitive market with competitors including TScan Therapeutics, Lyell Immunopharma, Hummingbird Bioscience, GigaGen and Shattuck Labs, among others.
- Headquarter San Diego, United States
- Employees 64 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Boundless Bio, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$65.36 M (USD)-32.22as on Dec 31, 2024
-
EBITDA
-$72.18 M (USD)-34.07as on Dec 31, 2024
-
Total Equity Funding
$251.99 M (USD)
in 4 rounds
-
Latest Funding Round
$100 M (USD), Series C
May 16, 2023
-
Investors
Fidelity Investments
& 20 more
-
Employee Count
64
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Boundless Bio
Boundless Bio is a publicly listed company on the NASDAQ with ticker symbol BOLD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Boundless Bio
Boundless Bio offers a comprehensive portfolio of products and services, including ecDTx Therapies.
Therapies targeting extrachromosomal DNA in oncogene amplified cancers
People of Boundless Bio
Unlock access to complete
Unlock access to complete
Funding Insights of Boundless Bio
Boundless Bio has successfully raised a total of $251.99M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $100 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Boundless Bio
Boundless Bio has secured backing from 21 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Bayer and ARE.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sectoral Asset Management is focused on global healthcare investment.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on life science companies
|
Locked | Locked | Locked | |
|
PE firm investing in the US
|
Locked | Locked | Locked |
Investor details for Boundless Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Boundless Bio
Investment portfolio details for Boundless Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Boundless Bio
Detailed financials for Boundless Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Boundless Bio Comparisons
Peer comparison for Boundless Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Boundless Bio
Boundless Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as TScan Therapeutics, Lyell Immunopharma, Hummingbird Bioscience, GigaGen and Shattuck Labs, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| Locked | Locked | Locked |
CAR-T and TIL immunotherapies for solid tumors are developed.
|
|
| Locked | Locked | Locked |
Antibody drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
|
| Locked | Locked | Locked |
An immunotherapy platform for oncology and other diseases is developed.
|
|
| Locked | Locked | Locked |
Viral immunotherapies are developed for cancer treatment.
|
Detailed competitors of Boundless Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Boundless Bio
Complete news archive for Boundless Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Boundless Bio
Boundless Bio was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Boundless Bio is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Boundless Bio is a funded company, having raised a total of $251.99M across 4 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Boundless Bio is 64.
Boundless Bio was founded in 2018 and is headquartered in San Diego, United States. Operations center on the biotechnology sector, where therapeutics are developed to address cancer through targeting extrachromosomal DNA (ecDNA). Emphasis is placed on ecDNA biology to create treatments for patients with oncogene-amplified cancers that are difficult to manage. The companys domain is boundlessbio.com.
Boundless Bio's top competitors include Hummingbird Bioscience, Lyell Immunopharma and GigaGen.
Boundless Bio offers ecDTx Therapies.
Yes, Boundless Bio is publicly traded on NASDAQ under the ticker symbol BOLD.
Boundless Bio has 21 investors. Key investors include Fidelity Investments, Bayer, ARE, Citadel, and RA Capital.
The ticker symbol of Boundless Bio is BOLD on NASDAQ.